scholarly journals Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives

2019 ◽  
Vol 9 ◽  
Author(s):  
Chaogang Yang ◽  
Fangfang Chen ◽  
Shuyi Wang ◽  
Bin Xiong
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Current Status ◽  
Gastrointestinal Cancers ◽  
Future Perspectives

scholarly journals Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value

2020 ◽  
Vol 21 (5) ◽  
pp. 1671 ◽  
Author(s):  
Anna Fabisiewicz ◽  
Malgorzata Szostakowska-Rodzos ◽  
Anna J. Zaczek ◽  
Ewa A. Grzybowska
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cancer Biology ◽  
Cancer Metastasis ◽  
Metastatic Breast ◽  
Breast Cancer Metastasis ◽  
Current Status ◽  
Molecular Profile ◽  
Breast Cancer Patients

Breast cancer metastasis is the leading cause of cancer deaths in women and is difficult to combat due to the long periods in which disseminated cells retain a potential to be re-activated and start the relapse. Assessing the number and molecular profile of circulating tumor cells (CTCs) in breast cancer patients, especially in early breast cancer, should help in identifying the possibility of relapse in time for therapeutic intervention to prevent or delay recurrence. While metastatic breast cancer is considered incurable, molecular analysis of CTCs still have a potential to define particular susceptibilities of the cells representing the current tumor burden, which may differ considerably from the cells of the primary tumor, and offer more tailored therapy to the patients. In this review we inspect the routes to metastasis and how they can be linked to specific features of CTCs, how CTC analysis may be used in therapy, and what is the current status of the research and efforts to include CTC analysis in clinical practice.

scholarly journals The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Zengli Fang ◽  
Jin Xu ◽  
Bo Zhang ◽  
Wei Wang ◽  
Jiang Liu ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Noncoding Rnas ◽  
Current Status ◽  
Cancer Therapies ◽  
Cancer Associated Fibroblasts ◽  
Biological Processes ◽  
Future Perspectives ◽  
Metabolic Characteristics ◽  
Complex Regulatory Network

AbstractAs the most important component of the stromal cell population in the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) are crucial players in tumor initiation and progression. The interaction between CAFs and tumor cells, as well as the resulting effect, is much greater than initially expected. Numerous studies have shown that noncoding RNAs (ncRNAs) play an irreplaceable role in this interplay, and related evidence continues to emerge and advance. Under the action of ncRNAs, normal fibroblasts are directly or indirectly activated into CAFs, and their metabolic characteristics are changed; thus, CAFs can more effectively promote tumor progression. Moreover, via ncRNAs, activated CAFs can affect the gene expression and secretory characteristics of cells, alter the TME and enhance malignant biological processes in tumor cells to contribute to tumor promotion. Previously, ncRNA dysregulation was considered the main mechanism by which ncRNAs participate in the crosstalk between CAFs and tumor cells. Recently, however, exosomes containing ncRNAs have been identified as another vital mode of interaction between these two types of cells, with a more direct and clear function. Gaining an in-depth understanding of ncRNAs in CAFs and the complex regulatory network connecting CAFs with tumor cells might help us to establish more effective and safer approaches for cancer therapies targeting ncRNAs and CAFs and offer new hope for cancer patients.

Role of omega-3 polyunsaturated fatty acids in preventing gastrointestinal cancers: current status and future perspectives

2018 ◽  
Vol 18 (12) ◽  
pp. 1189-1203 ◽  
Author(s):  
Ho-Jae Lee ◽  
Young-Min Han ◽  
Jeong Min An ◽  
Eun A. Kang ◽  
Yong Jin Park ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Current Status ◽  
Gastrointestinal Cancers ◽  
Omega 3 ◽  
Future Perspectives

Circulating tumor cells detected in patients with gastrointestinal cancers associate with tumor stage and response to chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4635-4635
Author(s):  
K. Hiraiwa ◽  
H. Takeuchi ◽  
Y. Kitagawa ◽  
H. Hasegawa ◽  
Y. Saikawa ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Stage Iv ◽  
Tumor Stage ◽  
Stage Iii ◽  
Advanced Tumor Stage ◽  
Gastrointestinal Cancers ◽  
Pleural Dissemination ◽  
Healthy Donors ◽  
Response To Chemotherapy

4635 Background: Circulating tumor cells (CTCs) in metastatic breast cancer has been reported to correlate with shorter overall survival. The purpose of this study was to clarify the clinical significance of CTCs in gastrointestinal cancers. Methods: CTCs of 108 patients with stage III or IV gastrointestinal cancers and 38 healthy volunteers were measured by use of the CellSearch system. Correlation between CTC counts and clinicopathologic variables was examined. Results: The number of CTCs in stage IV patients (23.0 ± 109.1) was significantly larger than that in healthy donors (0.1 ± 0.2) and that in stage III patients (0.4 ± 1.8) (p < 0.001). =2 CTCs were more frequently found in stage IV patients (41.6%) than in healthy donors (0%) and in stage III patients (3.2%) (p < 0.001). =2 CTCs in gastric or colorectal cancer had significant correlation with peritoneal dissemination (p = 0.029). =2 CTCs in esophageal cancer had significant correlation with pleural dissemination (p = 0.030). In 10 of 32 CTC positive (=2) patients with stage IV gastrointestinal cancers, CTC was measured before initiation of a new line of chemotherapy and more than 3 weeks after initiation of therapy. The change in CTCs correlated with disease progression and reflected chemotherapeutic effect. Conclusions: This study suggested measurement of CTCs in gastrointestinal cancer patients shows promise as a tool for judging advanced tumor stage, predicting peritoneal or pleural dissemination and monitoring response to chemotherapy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document